Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL840800 | 0.97 | — | — | |
| SCHEMBL483875 | 0.72 | — | — | |
| Water SCHEMBL28177570 | 0.69 | — | — | |
| SCHEMBL5224306 | 0.67 | — | — | |
| SCHEMBL23611178 | 0.67 | — | — | |
| SCHEMBL28108445 | 0.67 | — | — | |
| SCHEMBL9063926 | 0.67 | — | — | |
| SCHEMBL8190321 | 0.67 | — | — | |
| SCHEMBL31673513 | 0.65 | — | — | |
| SCHEMBL1669939 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858387-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | Seagen Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3778917-A2 | MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS, AND METHODS | F. Hoffmann-La Roche AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-10918735-B2 | Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2020-11-05 | — | — | US | disclosed |
| US-10808039-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10584181-B2 | Methods of making and using multispecific antibody panels and antibody analog panels | GENENTECH, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190338045-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2019-11-07 | — | — | US | disclosed |
| US-10414826-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190255187-A1 | SUBSTITUTED PYRAZINO[1',2':1,5]PYRROLO[2,3-B]INDOLE-1,4-DIONES FOR CANCER TREATMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3505191-A1 | AURISTATINS HAVING AN AMINOBENZOIC ACID UNIT AT THE N TERMINUS | Seattle Genetics, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20060182751-A1 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2006-08-17 | — | — | US | disclosed |
| WO-2006060533-A2 | CONJUGATES OF 1, 8-BIS-NAPHTHALIMIDES WITH AN ANTIBODY | GENENTECH, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060074008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEAGEN INC. | 2006-04-06 | — | — | US | disclosed |
| WO-2006034488-A2 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20050238649-A1 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2005081711-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1545613-A2 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | Seattle Genetics, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004010957-A2 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-0220899-B1 | BIFUNCTIONAL LINKER | Immunomedics, Inc. (US) | 1992-03-11 | — | — | EP | disclosed |
| US-4680338-A | Bifunctional linker | IMMUNOMEDICS, INC. (US) | 1987-07-14 | — | — | US | disclosed |